GRAY vs. CYCN, OBSV, TRVN, VAXX, BNOX, CANF, EFTR, OGEN, VIRI, and HEPA
Should you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include Cyclerion Therapeutics (CYCN), ObsEva (OBSV), Trevena (TRVN), Vaxxinity (VAXX), Bionomics (BNOX), Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Oragenics (OGEN), Virios Therapeutics (VIRI), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "pharmaceutical preparations" industry.
Graybug Vision (NASDAQ:GRAY) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
Cyclerion Therapeutics received 18 more outperform votes than Graybug Vision when rated by MarketBeat users. Likewise, 58.62% of users gave Cyclerion Therapeutics an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote.
49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by company insiders. Comparatively, 13.1% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Graybug Vision had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 1 mentions for Graybug Vision and 0 mentions for Cyclerion Therapeutics. Graybug Vision's average media sentiment score of 0.58 beat Cyclerion Therapeutics' score of 0.00 indicating that Graybug Vision is being referred to more favorably in the media.
Cyclerion Therapeutics has higher revenue and earnings than Graybug Vision.
Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500.
Graybug Vision's return on equity of -77.61% beat Cyclerion Therapeutics' return on equity.
Summary
Cyclerion Therapeutics beats Graybug Vision on 8 of the 11 factors compared between the two stocks.
Get Graybug Vision News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Graybug Vision Competitors List
Related Companies and Tools
